Crown Laboratories, Inc. and Hildred Capital have acquired Revance Therapeutics, Inc.
Crown will buy Revance at $3.65 per share, and Revance will be delisted from NASDAQ following the acquisition.
“We are excited to officially welcome Revance to the Crown family,” says Jeff Bedard, Founder and Chief Executive Officer of Crown, in a news release. “This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers, with what we believe is a comprehensive portfolio that represents the three pillars of facial aesthetics – relax, restore, and regenerate – and we will support these offerings with a highly trained and experienced sales force. We are well-positioned to become a global leader in the aesthetics and skincare industry and will leverage our combined resources to create long-term value for our stakeholders.”
